Jean Fan

NeoImmuneTech Appoints Jean Fan, M.D., as Chief Clinical Officer

Retrieved on: 
Wednesday, August 25, 2021

NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced the appointment of Jean Fan, M.D., as Chief Clinical Officer (CCO).

Key Points: 
  • NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced the appointment of Jean Fan, M.D., as Chief Clinical Officer (CCO).
  • Fan brings over 20 years of experience in oncology and hematology leadership and clinical development to this role.
  • Fans contributions to our Clinical Development team thus far, and I am pleased to welcome her to the newly created role of Chief Clinical Officer, said Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech (NIT).
  • Fan joined NIT in 2020 as VP, Head of Clinical Development, coming from Blueprint Medicines where she served as VP, Clinical Development.